ClinicalTrials.gg
RecruitingNCT02381301Updated Mar 28, 2017

Biomarkers and Cardiac CT

An observational study in Coronary Artery Disease and Atherosclerosis, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by Maastricht University Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Coronary Artery Disease by Maastricht University Medical Center — 2 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Maastricht University Medical Center.

Started
2015
with 1 other
Observational
6 of 11
2 open now
Registered
7th of 11
by date

Among the 11 studies in Coronary Artery Disease by Maastricht University Medical Center, this one is one of 2 that started in 2015, is one of 6 observational ones, and was the 7th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 11 studies in Coronary Artery Disease by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by Maastricht University Medical Center, or all of them as a file.
02

Study summary

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge.

One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.

03

Conditions studied

  • Coronary Artery Disease
  • Atherosclerosis

Keywords

  • Biological Markers
  • Multidetector Computed Tomography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients referred from the Cardiology clinic for routine CCTA for diagnostic purposes, will be included in this study, after given written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients referred from the Cardiology clinic for routine CCTA.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Severe renal insufficiency
  • Severe allergy to contrast medium
  • Inability to obtain
  • Age below 18 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Venous blood sampling prior to CCTA.

    In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.

    Biological: Venous blood sampling prior to CCTA.

Interventions

  • BiologicalVenous blood sampling prior to CCTA.
06

What researchers measure

Primary outcomes

  1. Data registration of patients undergoing CCTA and given written informed consent.

    Time frame: 15 years.

  2. To detect these patients for cardiovascular disease and Long term CV outcome (MACE).

    Time frame: 15 years.

Secondary outcomes

  1. The relationship of novel blood biomarkers with CCTA findings.

    Time frame: 15 years.

  2. The predictive value of these biomarkers to predict CAD in patients undergoing CCTA.

    Time frame: 15 years.

  3. The prognostic value of these biomarkers (in combination) to predict MACE.

    Time frame: 15 years.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Dec 2029 and a completion of Dec 2029. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2015
First posted
Mar 6, 2015
Start
Feb 2015
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Mar 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02381301
Responsible party
Sponsor
First posted
Mar 6, 2015
Start date
Feb 2015
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Mar 28, 2017

Study contacts

Bas Kietselaer, MD, PhD
Contact
b.kietsealer@mumc.nl
+31433871587
Sibel Altintas, MD
Contact
s.altintas@mumc.nl
+31433881232
Harry J Crijns, MD, PhD
study chair · Maastricht University Medical Center
Bas Kietselaer, MD, PhD
principal investigator · Maastricht University Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion